journal cover

Protective immunity to tuberculosis with Ag85B-ESAT-6 in a synthetic cationic adjuvant system IC31

Vaccine

May 6, 2006

Else Marie AggerPeter Andersen

Abstract

In this study, we evaluated the potential of a novel synthetic adjuvant designated IC31 for the ability to augment the immune response and protective efficacy of the well-known mycobacterial vaccine antigen, Ag85B-ESAT-6. The IC31 adjuvant, consisting of a vehicle based on the cationic ...read more

Mentioned in this Paper

Real-Time Polymerase Chain Reaction
ESAT gene
Monoclonal Antibodies
Immune Response
T-Lymphocyte
Bacterial Proteins
Tuberculosis Vaccines
TLR4 gene
Mice, Inbred BALB C
Lung
54
Paper Details
References
  • References22
  • Citations68
123
  • References22
  • Citations68
12345...

Similar Papers Found In These Feeds

Tuberculosis

Tuberculosis is an infectious disease usually caused by Mycobacterium tuberculosis bacteria. Discover the latest research on tuberculosis here.

Malaria

Malaria is a mosquito-borne infectious disease that affects humans and other animals. Malaria causes symptoms that typically include fever, tiredness, vomiting, and headaches. Discover the latest research on malaria here,

Plasmodium Falciparum

Malaria remains a major cause of morbidity and mortality in the tropics, with the parasite Plasmodium falciparum responsible for the majority of the disease burden. Discover the latest research on Plasmodium falciparum.

Immunomodulating Agents

Immunomodulating agents are substances that stimulate or suppresse the immune system and may help the body combat againsts cancer, infection, or other diseases. Discover the latest research on immunomodulating agents here.

Avian Influenza: Innate Immune Adjuvant

Adjuvants systems that are added to vaccines against avian influenza have be explored to enhance the innate immune system response against the virus. Here is the latest research on avian influenza and the innate immune adjuvant.

© 2020 Meta ULC. All rights reserved

Protective immunity to tuberculosis with Ag85B-ESAT-6 in a synthetic cationic adjuvant system IC31

Vaccine

May 6, 2006

Else Marie AggerPeter Andersen

PMID: 16675077

DOI: 10.1016/j.vaccine.2006.03.072

Abstract

In this study, we evaluated the potential of a novel synthetic adjuvant designated IC31 for the ability to augment the immune response and protective efficacy of the well-known mycobacterial vaccine antigen, Ag85B-ESAT-6. The IC31 adjuvant, consisting of a vehicle based on the cationic ...read more

Mentioned in this Paper

Real-Time Polymerase Chain Reaction
ESAT gene
Monoclonal Antibodies
Immune Response
T-Lymphocyte
Bacterial Proteins
Tuberculosis Vaccines
TLR4 gene
Mice, Inbred BALB C
Lung
54

Related Papers

Paper Details
References
  • References22
  • Citations68
123
  • References22
  • Citations68
12345...
/papers/protective-immunity-to-tuberculosis-with-ag85b-esa/16675077